#ESCCongress – RCT: In patients with A. Fibrillation who under | Cardiology

#ESCCongress – RCT: In patients with A. Fibrillation who underwent TAVR, Edoxaban was noninferior to Vit. K Antagonist regarding the composite primary outcome of adverse clinical events, but resulted in a higher incidence of major bleeding.

https://www.linksmedicus.com/news/esccongress-rct-patients-fibrillation-underwent-tavr-edoxaban-noninferior-vit-k-antagonist-regarding-composite-primary-outcome-adverse-clinical-events-resulted/